Adapting to the AI Era: Simulating Patient and Physician Perspectives at Scale
As recently profiled in the New York Times, the rise of AI chatbots in healthcare is fundamentally changing how patients form […]
Insights
Is AI at the helm of biopharma business development strategies?
Jacqueline Poot President – Strategic Consulting & Analytics BU IDEA Pharma As a moderator of this session at BIOEuropeSpring, my
Acceptance of Campfire Session at 39th ECNP Congress 2026 Highlighting Urgent Need to Rethink Development in CIAS
IDEA Pharma Announces Acceptance of Campfire Session at 39th ECNP Congress 2026 Highlighting Urgent Need to Rethink Development in CIAS
The Emerging Innovative Pharmaceutical Enterprises in China
Building on the China Pharmaceutical Innovation and Invention Index, which assesses the overall innovation strength of leading Chinese pharmaceutical companies, here
Revitalizing Pharma Collaborations: The Reblozyl Case Study
In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the
Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan
In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine
What Works, What Kills What, and Why It Matters By Mike Rea In pharmaceutical R&D, where billions ride on the
Minimizing Bias in Market Research: An Interview with Erik Coats
Minimizing Bias in Market Research: An Interview with Erik Coats By The Fulcrum Research Division Erik Coats is one of
2025 Collaborating for Novel Solutions (CNS) Summit: Annual Pharma Digital Innovation Index, cements leaders in the Biopharmaceutical innovation of digital solutions.
Tuesday, November 4th, 2025, Boston, MA – Today, the annual Pharmaceutical Digital Innovation Index, a partnership between IDEA Pharma, a
Challenges and Concerns Raised by EFPIA on Joint Clinical Assessments
In the healthcare regulation sphere, proposed EU-level joint clinical assessments (JCAs) have sparked debate in the pharmaceutical industry. A recent EFPIA report highlights concerns about the rigidity of the guidelines, particularly in oncology, and suggests revisions to ensure a more efficient and adaptable evaluation process that accommodates diverse stakeholder needs across Europe.